Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells
International Journal of Medical Sciences · 2023
DOI: 10.7150/ijms.87134 ↗At a glance
Journal article in International Journal of Medical Sciences, 2023. Written by Qingqing Li and 13 co-authors. Institution: Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China. Major MEDLINE topics: Rabies virus, Rabies, Rabies Vaccines. Cited 6 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Rabies continues to be a huge threat to public health. The rabies virus envelope glycoprotein (RABV G) is a major rabies virus antigen and contains neutralizing epitopes, which are primary candidates for subunit vaccines and diagnostic antigens. However, the production and purification of rRABV G while retaining its antigenic and immunogenic remains to be a challenge. Here, we aimed to establish a platform for rRABV G production and purification, and determine the immunogenicity and antigenicity of rRABV G. The cDNA fragment encoding the soluble form of RABV G was synthesized and cloned into a lentiviral expressing vector. Recombinant lentiviral vector LV-CMV-RABV G-eGFP was packaged, titered, and then transduced into HEK 293T cells. The cell culture supernatant was purified using nickel affinity chromatography and subsequently confirmed through Western Blot analysis and indirect enzyme-linked immunosorbent assay (ELISA). The ELISA utilized human sera obtained from individuals who had been vaccinated with the human commercial Purified Vero Cells Rabies Vaccine (PVRV). Notably, we observed a neutralizing antibody response in immunized pigs rather than in mice. This discrepancy could potentially be attributed to factors such as the instability of the rRABV G protein, variations in host responses, and variances in the adjuvant used. Taking all these findings into account, the rRABV G protein generated in this study exhibits promise as a potential vaccine candidate for the prevention of rabies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China.
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
- Guangzhou Bioneeds Biotechnology CO., LTD, Guangzhou, 510000, China.
- Department of Nuclear Medicine, Yuxi People's Hospital of Yunnan Province,Yuxi, 653100, China.
- Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, 21205, USA.
- South China Institute of Biomedicine, Guangzhou, 510000, China.
Cite
APA
Li, Q., Yan, R., Bai, N., Tan, Z., Yu, Q., Su, H., Wei, X., Li, A., Chen, X., Li, Z., He, Y., Li, H., Li, X., & Mao, Y. (2023). Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.87134
Vancouver
Li Q, Yan R, Bai N, Tan Z, Yu Q, Su H, et al. Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells. International Journal of Medical Sciences. 2023. doi:10.7150/ijms.87134
BibTeX
@article{Li2023,
author = {Li, Qingqing and Yan, Renhe and Bai, Na and Tan, Zhenglan and Yu, Qing and Su, Heng and Wei, Xiwen and Li, Andrew and Chen, Xueji and Li, Zhenyu and He, Yuezhong and Li, Hongwei and Li, Xiangxin and Mao, Yingying},
title = {Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells},
journal = {International Journal of Medical Sciences},
year = {2023},
doi = {10.7150/ijms.87134}
}
EUVIMED